Proxy Results, Management Change/Compensation (Form 8-K)

On June 9, 2026, at the 2026 Annual Meeting of Stockholders (the "Annual Meeting") of TELA Bio, Inc. (the "Company"), the Company's stockholders approved the amendment (the "Plan Amendment") to the Company's Amended and Restated 2019 Equity Incentive Plan, as amended (the "A&R 2019 Plan"), to, among other things, increase the authorized shares issuable under the A&R 2019 Plan by 3,500,000 shares. The Plan Amendment previously had been approved, subject to stockholder approval, by the Board of Directors of the Company (the "Board"). The Plan Amendment became effective immediately upon stockholder approval at the Annual Meeting.

A description of the material terms of the Plan Amendment is contained in the Company's Definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2026 (the "Proxy Statement"). The foregoing description of the Plan Amendment and the summary contained in the Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the Plan Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

As of April 24, 2026, the record date for the Annual Meeting, there were 44,765,928 outstanding shares of the Company's common stock, par value $0.001 per share. The Annual Meeting was conducted virtually, and the following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting, which are described in detail in the Company's Proxy Statement.

(a)            Proposal 1 - Election of Class I Directors. Each of Joseph Capper, Betty Jo Rocchio and William Plovanic were elected to the Board to serve as Class I directors until the 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows:

(b)            Proposal 2 - Ratification of Independent Registered Public Accountant. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the 2026 fiscal year was ratified, as follows:

(c)            Proposal 3 - Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. The stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, as follows:

(d)           Proposal 4 - Approval of an amendment to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan to, among other things, increase the authorized shares issuable thereunder by 3,500,000 shares. The Plan Amendment was approved, as follows: